SKYRIZI
(skyrizi)PreclinicalBiologic
AbbVieSKYRIZI is one of 150 biologic programs targeting Psoriasis. It is currently in Preclinical.
4
Indications
0
Total Trials
0
Active Trials
149
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[2]
Competition
Competitive Landscape
107 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Zasocitinib
TakedaPhase 3
D-2570
IInventisBio Co., Ltd
Phase 3
TAK-279
TakedaPhase 3
Ponvory
VVanda Pharmaceuticals
Phase 3
SYHX1901
CCSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3
Vunakizumab (IL-17A Inhibitor)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
SHR-1314
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
HS-10374
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
ICP-488
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Regulatory
FDA Approval Timeline[3]
Apr 23, 2019
SKYRIZI
BLA BLA761105
Jun 16, 2022
SKYRIZI
BLA BLA761262
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for skyrizi. EMBL-EBI & Wellcome Sanger Institute.
- [3]
- [4]